Eastern Cooperative Oncology Group

东部肿瘤合作组

基本信息

批准号：
6898402
负责人：
DAVID H JOHNSON
金额：
$ 42.63万
依托单位：
VANDERBILT UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1989
资助国家：
美国
起止时间：
1989-05-01 至 2010-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6898402
关键词：
AIDS antineoplastics biological response modifiers blood /lymphatic neoplasm bone marrow transplantation brain neoplasms breast neoplasms cancer prevention clinical research clinical trials combination cancer therapy combination chemotherapy cooperative study data management data quality /integrity fluorescent in situ hybridization gastrointestinal neoplasms gene therapy head /neck neoplasm health behavior human subject human therapy evaluation leukemia lymphoma medical outreach /case finding melanoma minimal residual disease multiple myeloma neoplasm /cancer chemotherapy neoplasm /cancer genetics neoplasm /cancer immunotherapy neoplasm /cancer pharmacology neoplasm /cancer radiation therapy neoplasm /cancer surgery neoplasm /cancer vaccine nucleic acid sequence oncology pathology patient oriented research prognosis reproductive system neoplasm thorax neoplasm tissue resource /registry urinary tract neoplasms

AIDS antineoplastics biological response modifiers blood /lymphatic neoplasm bone marrow transplantation brain neoplasms breast neoplasms cancer prevention clinical research clinical trials combination cancer therapy combination chemotherapy cooperative study data management data quality /integrity fluorescent in situ hybridization gastrointestinal neoplasms gene therapy head /neck neoplasm health behavior human subject human therapy evaluation leukemia lymphoma medical outreach /case finding melanoma minimal residual disease multiple myeloma neoplasm /cancer chemotherapy neoplasm /cancer genetics neoplasm /cancer immunotherapy neoplasm /cancer pharmacology neoplasm /cancer radiation therapy neoplasm /cancer surgery neoplasm /cancer vaccine nucleic acid sequence oncology pathology patient oriented research prognosis reproductive system neoplasm thorax neoplasm tissue resource /registry urinary tract neoplasms

展开

项目摘要

DESCRIPTION (provided by applicant): The principal objectives of this grant are to secure funding to support the clinical research activity of the Eastern Cooperative Oncology Group (ECOG) at Vanderbilt University Medical Center, to facilitate patient accrual to ECOG trials, and to expand the scientific and administrative contributions made to ECOG by Vanderbilt investigators. The specific aims of the proposal are: 1) to increase participation in ECOG sponsored clinical trials, 2) to further increase the scientific and administrative contributions to ECOG by Vanderbilt investigators, 3) to continue the development of innovative treatment programs for common solid tumors and hematologic malignancies, 4) to provide basic science expertise for correlative laboratory projects attached to ECOG trials and 5) to maintain a high level of data quality and management for which this institution is known. These goals will be achieved through the close interaction of investigators from medical oncology, radiation oncology, pathology and the section of surgical sciences. The interactions between Vanderbilt and other ECOG institutions will be facilitated by the presence of Vanderbilt investigators on ECOG disease oriented and modality committees. The Vanderbilt-lngram Comprehensive Cancer Center has in place all the necessary elements for the successful execution of cooperative group clinical trials including an outstanding data management staff, excellent outpatient and inpatient facilities in which this work will be undertaken and a long history of cooperative group participation.

描述（由申请人提供）：这笔赠款的主要目标旨在确保资金支持范德比尔特大学医学中心东部合作肿瘤学小组（ECOG）的临床研究活动，以促进患者对ECOG试验的累计，并扩大Vanderbilt the vanderbilt研究者为ECOG所做的科学和行政贡献。该提案的具体目的是：1）增加参与ECOG赞助临床试验的参与，2）进一步增加范德比尔特研究人员对ECOG的科学和行政贡献，3）继续开发针对普通实体瘤和血液学恶性肿瘤的创新治疗计划，4）用于为易变的实验室提供质量和5）质量的质量和5），并为5）质量提供了AP）。已知。这些目标将通过医学肿瘤学，放射肿瘤学，病理和手术科学部分的研究人员的密切相互作用来实现。范德比尔特研究人员在面向ECOG疾病和模态委员会上的存在将促进范德比尔特与其他ECOG机构之间的相互作用。 Vanderbilt-Lngram综合癌症中心为成功执行合作集团临床试验的所有必要要素，包括出色的数据管理人员，出色的门诊病人和住院设施，并在其中进行这项工作以及合作小组参与的悠久历史。